Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Author: kodiac

L-Carnitine

Our opinion on this compoundResearch workhorse

30/100

FDA-approved mitochondrial cofactor with fully mapped biology and minimal frontier research value

Look, L-Carnitine is not a research compound in any meaningful frontier sense. It’s a cofactor. The biology has been worked out since Fritz identified its role in fatty acid oxidation in 1955, and by the time McGarry and Foster had fully characterized CPT I, CACT, and CPT II in the 1980s, the mechanism was essentially closed. Theres nothing left to discover about what levocarnitine does at the molecular level. That’s not an insult, it’s just the reality: the compound is an obligate shuttle for long-chain fatty acyl-CoA esters across the inner mitochondrial membrane, and that job is completely understood.

What it does have is an unusually clean FDA approval story. Carnitor has been approved for primary systemic carnitine deficiency, secondary deficiency in organic acidemias, and hemodialysis-related carnitine loss. Those indications rest on real clinical data, not preclinical extrapolation. The hemodialysis population in particular shows robust and replicated signal, because ESRD patients on long-term dialysis lose carnitine faster than they can synthesize it and the replacement effect is measurable. The cardiovascular secondary prevention literature is more complicated, with a 2013 JAMA Internal Medicine meta-analysis showing modest but real reductions in mortality and ventricular arrhythmia post-MI, though the effect size doesn’t set the field on fire.

For a serious bench investigator, the honest value proposition is narrow. If you’re studying primary carnitine deficiency, organic acidemias, or the OCTN2 transport system specifically, L-Carnitine belongs in your toolkit. It’s also a necessary comparator if you’re evaluating the esterified derivatives. What we don’t think it offers is a reason to run a new research program in 2025. ALCAR has a more interesting CNS bioavailability story, propionyl-L-carnitine has a distinct vascular smooth muscle angle, and neither of those is particularly novel either.

The TMAO concern adds a layer of complexity the research community is still sorting out: Koeth et al. (2013, Nature Medicine) established that gut microbiota convert L-carnitine to trimethylamine, which is then oxidized to TMAO, and elevated TMAO correlates with cardiovascular risk in epidemiological data. Whether this represents a real mechanistic liability for supplemental L-carnitine, or is confounded by red meat intake, is genuinely unresolved and that might be the most interesting open question the compound now carries. But that question belongs to microbiome researchers, not necessarily to the carnitine itself.

We rate this compound the way you’d rate a reference standard: useful in specific contexts, essential for deficiency-state research, and completely uncompelling as a novel target. A serious investigator would source it as a comparator or tool and move on.

Novelty

10

Mechanism promise

14

In-category differentiation

20

Evidence quality

62

Translational signal

58

Research bench value

33

Rationale L-Carnitine scores low on novelty and mechanism because it is a decades-old obligate cofactor with textbook-level understood biology; the CPT shuttle has been characterized since the 1970s Fritz and McGarry era. Evidence and translational scores pull the overall up modestly because the compound is an FDA-approved pharmaceutical with real clinical impact in deficiency states, but that approval actually underscores how mature and un-frontier this chemistry is.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous quaternary ammonium compound functioning as an obligate cofactor in mitochondrial long-chain fatty acid beta-oxidation via the carnitine palmitoyltransferase shuttle system

A conditionally essential nutrient and FDA-approved pharmaceutical (levocarnitine) that mediates the translocation of long-chain fatty acyl groups across the inner mitochondrial membrane, with clinical applications spanning primary and secondary carnitine deficiency, cardiovascular secondary prevention, hemodialysis support, exercise performance, male reproductive health, and neuroprotection.

Abstract

L-Carnitine (levocarnitine) is a naturally occurring, water-soluble quaternary ammonium compound biosynthesized from the amino acids lysine and methionine in liver, kidney, and brain, and obtained exogenously from dietary sources (principally red meat and dairy products) and from pharmaceutical or nutraceutical supplementation. The compound is an obligate cofactor for the carnitine palmitoyltransferase (CPT) shuttle system, the sole mechanism by which long-chain fatty acyl-coenzyme A esters cross the inner mitochondrial membrane to undergo beta-oxidation. In the absence of adequate carnitine, mitochondrial long-chain fatty acid oxidation is impaired, producing the metabolic phenotype of primary systemic carnitine deficiency: hypoketotic hypoglycemia, cardiomyopathy, skeletal myopathy, and hepatic encephalopathy. The compound was first isolated from vertebrate muscle extract by Gulewitsch and Krimberg in 1905, structurally characterized as beta-hydroxy-gamma-trimethylaminobutyric acid by Tomita and Sendju in 1927, identified as the insect growth factor vitamin BT by Fraenkel and colleagues in the 1950s, and functionally linked to fatty acid oxidation by Fritz in 1955. Its obligate role in mitochondrial bioenergetics was established through the subsequent characterization of the CPT I, carnitine-acylcarnitine translocase (CACT), and CPT II enzyme system by McGarry, Foster, Ramsay, and colleagues in the 1970s and 1980s.

L-Carnitine is approved by the United States Food and Drug Administration as levocarnitine (Carnitor, Leadiant Biosciences) for the treatment of primary systemic carnitine deficiency and for the prevention and treatment of carnitine deficiency in patients with end-stage renal disease undergoing maintenance hemodialysis. Pharmacokinetics are characterized by carrier-mediated intestinal absorption via the organic cation/carnitine transporter OCTN2 (SLC22A5), with oral bioavailability of 54 to 87 percent from dietary sources but only 14 to 18 percent from high-dose oral supplements owing to saturation of active transport. Renal handling is dominated by efficient tubular reabsorption (90 to 99 percent of filtered load) via OCTN2 at physiological plasma concentrations, with saturable reabsorption kinetics producing rapid urinary clearance of supraphysiological doses. Plasma elimination half-life is approximately 2 to 6 hours for exogenous doses; the endogenous total body pool (approximately 20 to 25 grams in a 70-kilogram adult) turns over slowly with an estimated whole-body half-life of 40 to 100 hours.

Clinical evidence for supplemental L-carnitine spans multiple therapeutic domains. In cardiovascular secondary prevention, a 2013 meta-analysis of 13 controlled trials (N = 3,629) by DiNicolantonio et al. in Mayo Clinic Proceedings reported a 27 percent reduction in all-cause mortality (OR 0.73, 95% CI 0.54 to 0.99), a 65 percent reduction in ventricular arrhythmias, and a 40 percent reduction in angina development in patients following acute myocardial infarction. In chronic heart failure, a 2017 meta-analysis of 17 trials (N = 1,625) reported significant improvements in left ventricular ejection fraction (+4.14%), stroke volume (+8.21 mL), and cardiac output (+0.88 L/min). In hemodialysis populations, Cochrane and systematic reviews have reported potential benefits for anemia, C-reactive protein reduction, and intradialytic hypotension, though evidence quality remains low to moderate. In exercise physiology, systematic reviews report benefits of 1 to 4 grams daily on VO2max, peak power output, and lactate reduction, with effect sizes dependent on dosing duration and exercise modality. In male reproductive health, meta-analyses report significant improvements in sperm motility and morphology with 1 to 3 grams daily for 3 to 6 months, though pregnancy rate improvements have not been consistently demonstrated. Acetyl-L-carnitine, a physiological ester derivative, has demonstrated efficacy in randomized controlled trials for diabetic peripheral neuropathy, with significant pain reduction and nerve fiber regeneration.

A safety consideration of growing importance is the gut microbial conversion of L-carnitine to trimethylamine (TMA), which undergoes hepatic oxidation by flavin-containing monooxygenase 3 (FMO3) to trimethylamine N-oxide (TMAO), a metabolite epidemiologically associated with increased atherosclerotic cardiovascular disease risk. The TMAO pathway is diet-dependent and microbiome-dependent, with omnivorous individuals producing substantially more TMAO from carnitine challenge than vegetarians or vegans. This monograph reviews the chemistry, biosynthesis, and transport of L-carnitine; the carnitine shuttle mechanism in molecular detail; the comprehensive pharmacokinetic record; the clinical evidence base across all studied indications; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event signal including the TMAO pathway; and a comparative assessment of five mitochondrial bioenergetic support compounds against L-carnitine on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1516Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
Retinalamin

Our opinion on this compoundSingle-lab provenance

34/100

Khavinson-paradigm retinal peptide bioregulator with CIS registration but no independent replication

Look, Retinalamin occupies a specific corner of ophthalmic neuroprotection: it’s a polypeptide fraction isolated from bovine retinal tissue, developed entirely within the Khavinson program at the St. Petersburg Institute of Bioregulation and Gerontology. That lineage matters. The same group produced Epitalon, Thymalin, Cortexin. The pattern holds across all of them: tissue-specific peptide cocktail, CIS registration, a body of clinical literature that reads as internally coherent but is essentially impossible to replicate independently. Retinalamin is the retinal entry in that series.

The mechanism concept is interesting in principle. Short peptides (mostly 2-7 residues) are proposed to modulate gene expression in a tissue-specific manner, acting on retinal photoreceptors, retinal pigment epithelium, and Muller glial cells. But interesting in principle isn’t well-characterized. The monograph itself flags limitations of mechanistic characterization, and theres no defined receptor, no known binding partner, no clear structure-activity relationship. It’s a heterogeneous mixture. That limits its value as a research probe because you can’t attribute an observed effect to a specific component, and you cant reproduce it with a defined chemical entity.

The clinical evidence covers open-angle glaucoma, diabetic retinopathy, retinal dystrophies, and some niche applications. There’s a Russian regulatory approval, which does require some evidentiary basis. What we like: this is an actual registered pharmaceutical, not a gray-market peptide. Thats a meaningful quality floor. What we don’t like: no phase 3 RCTs outside the CIS, no independent replication in Western academic labs, and no mechanistic validation using modern molecular tools. The studies are largely open-label, modest N, and originate from within the Geropharm ecosystem.

In ophthalmic neuroprotection broadly, the competition is serious. CNTF delivery devices (NT-501) have completed real phase 2 and 3 trials. Recombinant BDNF programs are advancing with defined molecular targets. Citicoline has a reasonably clean evidence base for optic neuropathy. Retinalamin’s differentiation is mostly institutional: it’s the retinal-specific polypeptide bioregulator, and it holds that slot because nobody else makes exactly this product. That’s not best-in-class; that’s an uncontested niche.

For bench investigators outside Russia, sourcing is complicated. Geropharm is the legitimate manufacturer but international access is limited, and research-grade alternatives carry authentication concerns that apply to any complex biological extract of animal origin. Honestly, for most programs studying retinal neuroprotection, better-characterized tools exist. The mechanism hypothesis here genuinely deserves more rigorous independent testing, and we’d like to see a Western lab attempt to fractionate this and identify active peptide components. But as a research priority right now, it scores low across almost every axis: novelty is modest, mechanism is opaque, evidence is single-consortium, and bench utility is constrained by heterogeneous composition that resists standard molecular attribution.

Novelty

38

Mechanism promise

36

In-category differentiation

40

Evidence quality

23

Translational signal

32

Research bench value

25

Rationale Retinalamin shares the core weakness of the broader Khavinson bioregulator program: clinical and mechanistic literature is dominated by a single consortium with no meaningful Western replication; the heterogeneous polypeptide composition limits bench utility and mechanistic attribution. Scoring reflects real CIS clinical use but appropriately discounts single-source evidence quality and opaque mechanism.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Polypeptide bioregulator complex derived from bovine retinal tissue with retinoprotective and neurotrophic activity

A tissue-derived polypeptide fraction developed at the St. Petersburg Institute of Bioregulation and Gerontology as a retinoprotective agent, distinguished from conventional neuroprotective ophthalmologics by its multi-peptide composition, tissue-specific gene expression regulation, and clinical application across glaucoma, diabetic retinopathy, and hereditary retinal dystrophies.

Abstract

Retinalamin is a complex of water-soluble polypeptide fractions with molecular weight not exceeding 10,000 daltons, isolated from bovine retinal tissue and developed as a retinoprotective peptide bioregulator by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology of the Russian Academy of Medical Sciences. The compound is registered in the Russian Federation and several Commonwealth of Independent States jurisdictions as a lyophilized preparation for parabulbar and intramuscular injection, manufactured by Geropharm LLC under the ATC code S01XA (other preparations for eye disease treatment). Retinalamin represents a distinct pharmacological class within ophthalmic neuroprotection: rather than a single molecular entity with a defined receptor target, it consists of a heterogeneous mixture of short-chain polypeptides (predominantly 2 to 7 amino acid residues in length) that act through tissue-specific modulation of gene expression, stimulation of intracellular protein synthesis, regulation of lipid peroxidation, and normalization of cellular membrane function in retinal photoreceptors, retinal pigment epithelium, and Mueller glial cells.

The mechanistic basis of Retinalamin activity has been characterized through in vitro and in vivo models at the St. Petersburg Institute. In Xenopus laevis early gastrula ectoderm assays, Retinalamin demonstrated concentration-dependent induction of neuronal differentiation including brain, retinal, and pigment epithelium lineages, establishing the compound as a morphogenetic peptide regulator with tissue-specific inductive capacity. In cell culture, Retinalamin and the related synthetic tetrapeptide Epithalon stimulated proliferation of retinal and pigmented epithelial cells in a tissue-specific and concentration-dependent manner. The proposed molecular mechanism involves sequential binding of constituent short peptides to promoter regions of genes involved in retinal cell differentiation, survival, and metabolic homeostasis, thereby modulating transcriptional activity and downstream protein expression. Pharmacodynamic effects observed in preclinical and clinical settings include stimulation of photoreceptor and retinal cellular element function, improvement of functional interactions between retinal pigment epithelium and photoreceptor outer segments, enhancement of Mueller cell activity and glutamate inactivation, normalization of vascular permeability, and reduction of oxidative stress through regulation of lipid peroxide metabolism.

Clinical evidence for Retinalamin spans multiple retinal pathologies. In compensated primary open-angle glaucoma, a 180-patient randomized controlled trial (Egorov et al. 2019) demonstrated that intramuscular Retinalamin produced significant retinoprotective effects, with improvement in mean deviation index from negative 5.52 to negative 4.82 decibels, stabilization of ganglion cell complex thickness (versus progressive thinning in controls), and preservation of pattern electroretinography amplitudes over the study period. A subsequent 147-patient randomized trial (Strakhov et al. 2020) demonstrated that biannual Retinalamin courses over 24 months arrested development of glaucomatous optic neuropathy, with retinal nerve fiber layer thickness remaining stable in treated patients versus declining from 83.5 to 76.7 micrometers in controls. In diabetic retinopathy, a 56-patient comparative study (Malakhova et al. 2024) provided objective structural and functional evidence of positive retinal changes with intramuscular Retinalamin in early-stage disease. In hereditary retinal dystrophies, long-term observational data (Razumovskiy et al.) demonstrated that a first course of Retinalamin improved visual acuity in 58.1 percent and visual fields in 64.5 percent of retinal degeneration patients, with repeated courses over 23 to 25 years preserving residual vision in 55.6 percent of patients and preserving object vision in 11.1 percent. In retinal abiotrophy, residual vision was preserved in 100 percent of treated cases. A 498-patient glaucoma study (Erichev et al. 2020) comparing intramuscular, retrobulbar, and combined administration routes demonstrated comparable efficacy across delivery methods, with total threshold retinal sensitivity increasing by 122 to 274 decibels across glaucoma stages.

The safety profile of Retinalamin is characterized by low adverse event rates. The principal reported events are local injection site reactions (pain, redness, swelling) and rare hypersensitivity reactions including anaphylactic shock and angioneurotic laryngeal edema. The compound is contraindicated during pregnancy (absence of clinical safety data) and in pediatric populations under 18 years for most indications. Pharmacokinetic characterization in the conventional sense is not feasible owing to the multi-component polypeptide composition, which does not permit standard absorption, distribution, metabolism, and elimination analysis of individual constituents. The standard clinical regimen consists of 5 to 10 milligrams administered once daily by parabulbar or intramuscular injection for 5 to 10 days, with courses repeated every 3 to 6 months. Retinalamin is not approved by the United States Food and Drug Administration, the European Medicines Agency, or other major Western regulatory authorities. The clinical evidence base is derived predominantly from Russian-language literature published in Vestnik Oftalmologii and related journals. Investigators outside the Russian Federation should approach the compound as a research-grade peptide preparation requiring independent analytical verification and should interpret the clinical literature with attention to the methodological standards and reporting conventions of the source publications.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1506Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
Cerebrolysin

Plain-language summaryIntrigue 65 / 100

Cerebrolysin is a porcine brain peptide hydrolysate used in Europe and Asia for stroke recovery and dementia. It contains a complex mixture of small peptides and amino acids. Available only as injection. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundSingle-lab provenance

42/100

Eastern European-dominant neuropeptide mixture with real clinical footprint but unverifiable, consortium-dominated evidence

Look, Cerebrolysin occupies a genuinely strange corner of the research landscape. It’s a porcine brain-derived peptide mixture that’s been a registered pharmaceutical in Austria, Russia, China, and roughly 50 other countries since the 1970s, yet you won’t find it approved in the US, Canada, or most of Western Europe. That regulatory asymmetry tells you something.

The mechanism story is legitimately interesting, if frustratingly hard to pin down. The preparation contains low-molecular-weight peptides with sequences homologous to BDNF, NGF, GDNF, and CNTF, plus about 15 percent free amino acids. In theory, hitting all four major neurotrophic axes simultaneously should be powerful. The problem is that it’s a mixture, and that creates an attribution nightmare at the bench. You can observe effects, but isolating which fraction is doing what is genuinely difficult. The BBB penetration data looks real in animal models, but the pharmacokinetics of a biological mixture don’t behave like a small molecule, and nothing in the existing literature isolates a clean dose-response for any individual constituent.

The evidence base is where things get uncomfortable. There are dozens of trials, including multi-center work in ischemic stroke (the CASTA trial) and Alzheimer’s disease. But the preponderance of that literature comes from Austrian, Eastern European, Russian, and Chinese research groups, often without the methodological rigor that Western journals demand. The replication problem is real. Independent labs haven’t picked this up the way they’ve validated BPC-157’s basic wound-healing biology, for instance. Decades of literature and verified evidence aren’t the same thing.

Differentiation within the neurotrophic preparation space is worth noting. Cerebrolysin is almost certainly the most studied compound in this class; competitors like Cortexin and Actovegin have even thinner evidence bases. Semax and P21 offer cleaner mechanism stories because they’re defined single molecules, which makes them better bench tools even if they lack Cerebrolysin’s clinical footprint. That’s a real trade-off worth thinking about before committing a research program to this compound.

What we like: the translational signal is real enough. Patients have been receiving this compound clinically for decades across a huge geographic range. The stroke and TBI indications have plausible mechanistic underpinning and some meaningful clinical effect size in compliant trials. What we dont like: that evidence is genuinely hard to appraise from outside the originating institutions. For a bench scientist who needs to build on existing literature, that opacity is a serious practical obstacle.

Honestly, Cerebrolysin is worth knowing about, particularly if your research program touches neuroprotection or neurotrophic biology. But don’t expect to pull clean mechanistic conclusions from the existing literature. The signal is there, somewhere in that mixture. Verifying it cleanly is the open problem.

Novelty

32

Mechanism promise

52

In-category differentiation

42

Evidence quality

40

Translational signal

48

Research bench value

38

Rationale Cerebrolysin’s multi-neurotrophic mechanism hitting BDNF, NGF, GDNF, and CNTF homologs simultaneously is conceptually interesting, and its registered pharmaceutical status across 50-plus countries reflects a non-trivial translational signal; however, the evidence base is overwhelmingly sourced from Austrian, Eastern European, and Asian research groups with poor independent replication, making it difficult for bench scientists to build confidently on the existing foundation.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Porcine brain-derived neurotrophic peptide mixture with multimodal neuroprotective and neurorestorative activity

A standardized enzymatic hydrolysate of porcine brain tissue yielding low-molecular-weight neuropeptides and free amino acids that cross the blood-brain barrier and exert neurotrophic, neuroprotective, and neuroplasticity-promoting effects across stroke, traumatic brain injury, and neurodegenerative disease models.

Abstract

Cerebrolysin is a standardized, injectable preparation of enzymatically derived low-molecular-weight neuropeptides and free amino acids obtained from porcine brain tissue, manufactured by EVER Neuro Pharma (formerly EBEWE Pharma) in Unterach, Austria. The preparation contains peptide fragments exclusively below 10,000 Daltons in molecular weight, including sequences homologous to brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), glial cell line-derived neurotrophic factor (GDNF), and ciliary neurotrophic factor (CNTF), together with approximately 15 percent free amino acids by mass. First developed in 1949 by Gerhard Harrer at the University of Graz and subsequently refined through enzymatic hydrolysis standardization at EBEWE Pharma beginning in 1972, the compound has been registered as a pharmaceutical product in over 50 countries (excluding the United States, Canada, the United Kingdom, and most Western European Union member states) for indications including stroke recovery, traumatic brain injury, and dementia syndromes.

The pharmacological profile of Cerebrolysin is characterized by multimodal neurotrophic and neuroprotective activity. The constituent peptides activate tropomyosin receptor kinase (Trk) signaling pathways, particularly TrkA and TrkB, initiating downstream MAPK/ERK and PI3K/Akt cascades that regulate neuronal survival, differentiation, and synaptic plasticity. Additional characterized mechanisms include inhibition of calpain-mediated cytoskeletal degradation, suppression of excitotoxic glutamate signaling, reduction of free radical formation, attenuation of microglial activation, and promotion of neurogenesis in the subventricular zone and hippocampal dentate gyrus. The low molecular weight of the constituent peptides permits transit across the blood-brain barrier, a property that distinguishes Cerebrolysin from recombinant full-length neurotrophic factors that do not achieve meaningful central nervous system concentrations after peripheral administration.

The clinical evidence base encompasses more than 200 clinical studies involving over 10,000 patients across stroke, traumatic brain injury, Alzheimer’s disease, vascular dementia, and pediatric neurodevelopmental indications. The Cerebrolysin and Recovery After Stroke (CARS) randomized, placebo-controlled, double-blind multicenter trial demonstrated large superiority of Cerebrolysin (30 mL per day for 21 days) over placebo on the Action Research Arm Test at day 90 (Mann-Whitney estimator 0.71, 95 percent confidence interval 0.63 to 0.79, P less than 0.0001). The Cerebrolysin Acute Stroke Treatment in Asia (CASTA) trial in 1,070 patients did not demonstrate superiority on the primary endpoint (National Institutes of Health Stroke Scale at day 90), although post hoc analysis in severe stroke (NIHSS greater than 12) showed a trend favoring Cerebrolysin. In Alzheimer’s disease, a meta-analysis of randomized controlled trials demonstrated significant improvement in cognitive function (standardized mean difference negative 0.40 on the ADAS-cog at 4 weeks) and global clinical change compared to placebo, with safety comparable to placebo. In traumatic brain injury, 27 clinical studies enrolling 9,752 patients have demonstrated improvements in consciousness level, cognitive performance, and neurological outcomes.

The safety profile across controlled clinical trials is favorable, with adverse event rates comparable to placebo in most analyses. The principal adverse events are vertigo, agitation, feeling hot, headache, and dizziness. Rare anaphylactic reactions have been reported. The compound is contraindicated in epilepsy and severe renal impairment. This monograph reviews the composition, manufacturing, and quality standardization of Cerebrolysin; the multimodal neurotrophic and neuroprotective pharmacology; the pharmacokinetic profile including blood-brain barrier penetration; the clinical evidence base across all studied indications; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event signal; and a comparative assessment of five neurotrophic or neuroprotective alternatives (Cortexin, P21, NSI-189, Actovegin, Semax) against Cerebrolysin on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation).

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1492Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
Elafibranor

Our opinion on this compoundEstablished, active research

59/100

Dual PPARalpha/delta agonist with approved PBC indication but a sobering NASH Phase 3 failure that narrows its research scope

Here’s the thing about elafibranor: it tells two very different stories depending on which indication you look at, and holding both in mind is essential for a fair assessment. The dual PPARalpha/delta mechanism is genuinely interesting pharmacology. PPARalpha drives hepatic fatty acid beta-oxidation and suppresses macrophage-mediated hepatic inflammation; PPARdelta modulates glucose uptake, macrophage polarization, and bile acid transporter expression. Combining both targets in a single molecule produces a pharmacological profile that single-target fibrates simply cant achieve, and Genfit’s GFT505 was designed with exactly that logic from the start.

The NASH story is where things get complicated. RESOLVE-IT, the Phase 3 in over 1,000 patients, hit interim futility in 2020 and was terminated. The GOLDEN-505 Phase 2b had shown a post-hoc signal at 120 mg, but post-hoc is post-hoc, and the Phase 3 said what it said. This matters because the dual PPARalpha/delta rationale was built largely on the NASH hypothesis: coordinated modulation of fatty acid oxidation and macrophage inflammation across multiple biological nodes simultaneously. The failure doesn’t invalidate the mechanism, but it does show the bench-to-clinic bridge in steatohepatitis is harder than rodent models implied.

The PBC pivot is where elafibranor earns its place. ELATIVE produced a signal thats difficult to argue with: 51 percent of patients on 80 mg achieved composite biochemical cholestasis response at week 52, versus 4 percent on placebo. Alkaline phosphatase normalization in 15 percent versus none on placebo. FDA accelerated approval followed in June 2024 under the trade name Iqirvo, EU authorization in September, NICE recommendation in October. Confirmatory trials are still running under the accelerated designation, so the evidence base isn’t fully mature, but the direction is clear and the effect size is large.

From a bench standpoint, elafibranor is a useful probe for dissecting PPARalpha versus PPARdelta contributions to hepatic bile acid signaling, particularly against seladelpar, the PPARdelta-selective agonist that also received FDA approval for PBC in August 2024. Whether the alpha component adds meaningful benefit over pure delta agonism is genuinely interesting open territory for investigators in this space. The active metabolite GFT1007 adds complexity: both parent and metabolite contribute to activity, and the CYP2C8/UGT1A3 pathway creates real drug-interaction questions in patients already on UDCA.

We think elafibranor belongs in a liver-focused research program and not much else. The NASH failure narrows scope, confirmatory data remains pending under accelerated approval, and utility outside hepatic PPAR biology is limited. The most interesting bench question is the alpha/delta contribution split versus seladelpar in PBC, and thats worth something. Solid approved drug in an underexplored rare disease indication; meaningful but not indispensable as a research tool.

Novelty

52

Mechanism promise

58

In-category differentiation

62

Evidence quality

67

Translational signal

67

Research bench value

48

Rationale Elafibranor’s ELATIVE Phase 3 delivered a compelling PBC signal (51% vs 4% biochemical response) and earned FDA accelerated approval in 2024, but the RESOLVE-IT NASH failure is a meaningful mark against the broader mechanism promise; dual PPARalpha/delta pharmacology is genuinely differentiated from single-target fibrates and FXR agonists, though seladelpar’s concurrent PBC approval introduces direct competition and leaves the alpha-contribution question unresolved.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Dual peroxisome proliferator-activated receptor alpha/delta (PPARalpha/delta) agonist with additional PPARgamma activity

A first-in-class dual PPARalpha/delta agonist developed by Genfit for hepatic steatoinflammatory and cholestatic liver diseases, granted FDA accelerated approval in June 2024 as Iqirvo for the treatment of primary biliary cholangitis in adults with inadequate response or intolerance to ursodeoxycholic acid.

Abstract

Elafibranor (GFT505) is a synthetic phenoxyalkanoic acid derivative and dual agonist of the peroxisome proliferator-activated receptor alpha (PPARalpha) and peroxisome proliferator-activated receptor delta (PPARdelta), with additional lower-potency agonist activity at the peroxisome proliferator-activated receptor gamma (PPARgamma). The compound activates PPARalpha with an EC50 of approximately 45 nanomolar and PPARdelta with an EC50 of approximately 175 nanomolar, producing a composite pharmacological profile that modulates hepatic fatty acid beta-oxidation, triglyceride metabolism, high-density lipoprotein cholesterol, bile acid synthesis and transport, glucose homeostasis, and macrophage-mediated hepatic inflammation through coordinated transcriptional regulation at both receptor subtypes. Elafibranor and its principal active metabolite GFT1007, formed by hydrolysis of the parent compound, both contribute to the pharmacological activity. The compound was discovered and initially developed by Genfit S.A. (Lille, France) for the treatment of nonalcoholic steatohepatitis (NASH), advancing through a Phase 2b trial (GOLDEN-505) in 274 patients that produced a post-hoc signal for NASH resolution without fibrosis worsening at the 120 mg daily dose, and into the Phase 3 RESOLVE-IT trial in over 1,000 patients, which was terminated in 2020 following an interim futility analysis that failed to demonstrate statistically significant separation from placebo on the primary endpoint. Development subsequently pivoted to primary biliary cholangitis (PBC), where elafibranor received FDA Breakthrough Therapy Designation in 2019 and demonstrated robust efficacy in the Phase 3 ELATIVE trial: 51 percent of patients receiving elafibranor 80 mg daily achieved a biochemical cholestasis response at week 52, compared to 4 percent on placebo, with alkaline phosphatase normalization in 15 percent of treated patients versus none on placebo. On June 10, 2024, the United States Food and Drug Administration granted accelerated approval to elafibranor (trade name Iqirvo, marketed by Ipsen) for the treatment of PBC in combination with ursodeoxycholic acid (UDCA) in adults with inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. European Union authorization followed in September 2024, and the United Kingdom National Institute for Health and Care Excellence (NICE) recommended elafibranor for National Health Service use in October 2024. Pharmacokinetics are characterized by high plasma protein binding (approximately 99.7 percent), a large apparent volume of distribution (approximately 4,731 liters), a long elimination half-life of the parent compound (approximately 60 to 70 hours), and metabolism of GFT1007 through CYP2C8, UGT1A3, and UGT2B7. The compound is generally well tolerated at the approved 80 mg daily dose; the principal adverse events in controlled trials were gastrointestinal (abdominal pain, diarrhea, nausea, and vomiting, each occurring in approximately 11 percent of treated patients versus 2 to 9 percent on placebo), weight gain, arthralgia, and musculoskeletal complaints including rare myopathy and rhabdomyolysis. Dose-dependent hepatotoxicity has been observed at supratherapeutic doses (exceeding 120 mg daily), with transaminase elevations above 5 times the upper limit of normal in approximately one-third of healthy volunteers at those exposures. The compound is contraindicated in decompensated cirrhosis and complete biliary obstruction and carries a warning for embryo-fetal toxicity. This monograph reviews the chemistry, synthesis, and structural class of elafibranor; the PPAR-mediated molecular pharmacology; the comprehensive pharmacokinetic profile including the GFT1007 active metabolite; the preclinical evidence in rodent models of steatohepatitis, fibrosis, and cholestasis; the clinical evidence base across NASH and PBC indications; sourcing and quality verification; reconstitution and handling; stack interactions and combinations; adverse events and safety signals; and a comparative assessment of five alternative agents (obeticholic acid, seladelpar, bezafibrate, fenofibrate, and saroglitazar) against elafibranor on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1515Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
ACD856

Our opinion on this compoundNovel, promising

64/100

First-in-class pan-Trk PAM with genuinely novel allosteric kinase mechanism, Phase 1 complete but pre-efficacy

Look, ACD856 is doing something genuinely different from every other neurotrophin-targeting approach we’ve seen reach clinical stages. Most attempts to amplify BDNF or NGF signaling have hit the same wall: direct agonism triggers pain, hyperalgesia, and proliferative effects that kill the program. ACD856 sidesteps that by binding the intracellular kinase domain of TrkA, TrkB, and TrkC and increasing the maximal catalytic velocity rather than mimicking the ligand. It potentiates what’s already there, spatiotemporal specificity intact. That’s not a minor pharmacological distinction, and it’s why the allosteric approach has attracted serious interest where orthosteric Trk programs kept failing.

The scaffold itself is interesting. AlzeCure’s team identified this triazinetrione series through a high-throughput screen of roughly 25,000 compounds and then optimized the lead away from ponazuril (the veterinary antiparasitic ancestor, ACD855) specifically to shorten the elimination half-life to something compatible with once-daily human dosing. That tells you the medicinal chemistry work was deliberate, not lucky. EC50 values sit at 295 nM at TrkB and roughly 330 nM at TrkC, with TrkA slightly weaker at 382 nM. Additional activity at IGF1R and FGFR1 adds an interesting layer, though we’re honest that it complicates clean mechanistic interpretation and warrants careful off-target profiling as the program matures.

What we like about the development status: AlzeCure has completed Phase 0 (IV microdose), Phase 1 SAD, and Phase 1 MAD studies. The compound behaves in humans, pharmacokinetics are characterized, and Phase IIa is in planning. That’s a real clinical footprint for a compound this novel. What we dont like: there is zero human efficacy data yet. None. The translational story is entirely preclinical, cognitive enhancement models in rodents, neurite outgrowth markers, antidepressant-like signals, TBI models. Solid work across multiple indication-relevant assays, but we’ve all seen preclinical Alzheimer’s candidates look exactly this good before failing spectacularly in Phase 2.

The competitive landscape is worth noting. E2511 from Eisai is pursuing Trk-targeting territory and represents a credible competitor worth tracking. By contrast, 7,8-DHF is a partial TrkB agonist with poor CNS penetration and a short half-life that makes it a weak comparator, and LM22A-4 has similar limitations. ACD856 is the cleanest clinical-stage candidate in this specific mechanism class right now, and thats a real structural advantage. But best-in-an-early-stage-field is not the same as validated pharmacology in the target population.

As a bench tool, a selective pan-Trk PAM with sub-micromolar potency across all three receptors would be genuinely useful for dissecting neurotrophin signaling biology. The current toolkit for TrkB work specifically is mediocre; 7,8-DHF has enough liabilities that investigators routinely apologize for using it. If ACD856 becomes more broadly available to academic labs, its probe value improves considerably. Right now availability is the limiting factor given its proprietary status. We score this 64: the mechanism and novelty are real, the evidence base is thin, and the translational signal is preclinical-only. Worth watching closely as Phase IIa readouts come in.

Novelty

78

Mechanism promise

80

In-category differentiation

68

Evidence quality

42

Translational signal

40

Research bench value

65

Rationale ACD856 scores high on novelty and mechanism (first-in-class triazinetrione Trk-PAM, intracellular kinase domain allosterism increasing Vmax rather than substituting for ligand, pan-TrkA/B/C coverage) but evidence quality and translational signal are bounded by Phase 1 PK and safety data only, with zero human efficacy readout; differentiation is real but E2511 from Eisai represents credible competition in the same mechanistic space.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Triazinetrione positive allosteric modulator of tropomyosin receptor kinases (TrkA, TrkB, TrkC) potentiating neurotrophin signaling

A first-in-class triazinetrione pan-Trk positive allosteric modulator developed by AlzeCure Pharma that enhances BDNF and NGF signaling for the treatment of cognitive dysfunction in Alzheimer’s disease, with additional preclinical support for depression, traumatic brain injury, and sleep disorders.

Abstract

ACD856 is a novel, orally bioavailable triazinetrione compound functioning as a positive allosteric modulator (PAM) of the tropomyosin receptor kinases TrkA, TrkB, and TrkC, the principal signal-transducing receptors for the neurotrophins nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophin-3 (NT-3), respectively [1, 2]. The compound was identified through a high-throughput screening campaign of approximately 25,000 compounds and structurally optimized from the veterinary antiparasitic triazinetrione scaffold shared by toltrazuril and ponazuril (ACD855), with the critical improvement of a substantially shortened elimination half-life suitable for once-daily human dosing [3, 4]. ACD856 potentiates the tropomyosin receptor kinases with EC50 values of 382 nM (TrkA), 295 nM (TrkB), and approximately 330 nM (TrkC), and exhibits additional positive allosteric modulation of the insulin-like growth factor 1 receptor (IGF1R) and fibroblast growth factor receptor 1 (FGFR1) [1, 5]. The mechanism of action is distinct from orthosteric Trk agonism: ACD856 binds the intracellular kinase domain of Trk receptors and increases the maximal catalytic velocity (Vmax) of the kinase, thereby amplifying endogenous neurotrophin signaling rather than substituting for it [2, 6]. This allosteric mechanism preserves the spatiotemporal specificity of native neurotrophin activity, a property expected to confer a more favorable safety profile than direct agonist approaches that have historically been limited by pain, hyperalgesia, and off-target proliferative effects.

In preclinical pharmacology, ACD856 has demonstrated reversal of scopolamine-induced and dizocilpine (MK-801)-induced memory impairment in passive avoidance and novel object recognition tasks in mice, restoration of age-related memory deficits in 21-month-old mice to the performance level of young animals following single-dose administration, neuroprotection against amyloid-beta(1-42)-induced synaptotoxicity in primary cortical neurons, enhancement of NGF-stimulated neurite outgrowth in PC12 cells, elevation of BDNF protein levels in the brains of aged mice following repeated dosing, and sustained antidepressant-like effects in the forced swim test persisting up to seven days after the last dose [5, 7, 8]. The compound also enhanced mitochondrial ATP production under energy-deprived conditions, increased phosphorylation of TrkB and ERK1/2 in cortical neurons, elevated hippocampal concentrations of serotonin, noradrenaline, and dopamine by in vivo microdialysis, and increased expression of the presynaptic protein SNAP25, collectively indicating a broad neuroprotective and neuroplasticity-promoting pharmacological profile [5, 7].

ACD856 has completed two Phase 1 clinical studies in healthy volunteers. The single ascending dose (SAD) study (1 to 150 mg oral, n = 56) demonstrated rapid absorption (median tmax 0.33 to 1.0 hours), linear dose-proportional pharmacokinetics, near-complete oral bioavailability (approximately 93 percent relative bioavailability), a terminal elimination half-life of approximately 20 hours supporting once-daily dosing, and an acceptable safety profile with no serious adverse events and no dose-related safety signals [9]. The multiple ascending dose (MAD) study (10, 30, and 90 mg daily for seven days, n = 24) confirmed dose-dependent increases in cerebrospinal fluid concentrations (geometric mean 3.98 to 100 ng/mL), CSF-to-unbound-plasma ratios of 0.37 to 1.20 indicating substantial blood-brain barrier penetration, dose-dependent changes on quantitative electroencephalography (increased theta power and theta/beta ratio) consistent with central target engagement, and continued safety and tolerability with no serious adverse events [10, 11]. AlzeCure Pharma has received a EUR 2.5 million grant from the European Innovation Council to conduct a Phase IIa clinical study of ACD856 in Alzheimer’s disease, with higher doses to be evaluated based on the favorable Phase 1 safety profile [12]. Additional indications under preclinical investigation include depressive disorders, traumatic brain injury, sleep disorders, and postoperative cognitive dysfunction.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1529Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
Masteron

Our opinion on this compoundEstablished workhorse

25/100

Historically approved DHT-derived AAS displaced by superior agents, offering minimal modern research priority

Look, Masteron is one of those compounds where the story is almost entirely historical. Drostanolone propionate was synthesized at Syntex in 1959, got FDA approval for palliative breast cancer treatment in 1961, and spent roughly two decades as a legitimate oncology agent before tamoxifen made it essentially redundant. Thats the arc in a sentence.

The chemistry is genuinely interesting from a structure-activity standpoint and we want to be fair to it. The 2-alpha-methyl substitution on the DHT backbone confers resistance to 3-alpha-hydroxysteroid dehydrogenase metabolism in skeletal muscle, which is why drostanolone retains measurable anabolic activity where unmodified DHT is rapidly inactivated. The compound also cant be aromatized, so you get clean AR agonism without estrogenic conversion, which was actually the pharmacologically relevant feature for estrogen-sensitive postmenopausal mammary carcinoma. That’s an elegant exploitation of a known metabolic vulnerability. The problem is that elegant and novel are not the same thing. This mechanism has been picked apart for 65 years. There is nothing left to discover about how drostanolone binds AR.

The evidence base for the registered indication is real but dated in ways that matter. The breast cancer trials from the late 1960s and early 1970s were small by modern standards, variably blinded, and used response criteria that don’t map to contemporary oncology endpoints. The compound worked in context. But that clinical chapter closed decisively when SERMs and aromatase inhibitors arrived, and there is no active development program in any indication today. What remains in the literature are observational studies, narrow androgen physiology investigations, and performance-context reports that don’t constitute translatable bench research.

As an AR agonist probe, testosterone and DHT are more accessible reference compounds with deeper characterization literature. If selective AR modulation with tissue specificity is the question, the SARM literature has structurally and pharmacologically surpassed anything a 1959 androstane derivative can offer. The differentiation case for drostanolone in a modern research program depends entirely on the 3-alpha-HSD resistance story, which is pharmacologically legitimate but not under active investigation anywhere serious we can identify.

Scheduling is worth noting: drostanolone is Schedule III in the United States under the Anabolic Steroid Control Act. That adds real regulatory friction to a research protocol without any offsetting scientific upside. Hepatotoxicity is minimal relative to 17-alpha-alkylated AAS given the absence of that modification, but the scheduling status imposes compliance overhead that has to be weighed against what you’re actually going to learn. Honestly, the answer here is: not much that isn’t already known. Worth understanding for DHT analog SAR context, not a priority for active research time in 2026.

Novelty

15

Mechanism promise

22

In-category differentiation

28

Evidence quality

42

Translational signal

22

Research bench value

28

Rationale Drostanolone is a 65-year-old androstane steroid whose only registered indication was rendered obsolete by tamoxifen and aromatase inhibitors; the structural features are pharmacologically coherent but exhaustively characterized, and there is no active development program or emerging indication to drive research interest in 2026. Schedule III cap (75) does not bind since raw score falls well below it.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic anabolic-androgenic steroid; 2-alpha-methyl-5-alpha-dihydrotestosterone 17-beta-propionate ester (androstane-derived androgen receptor agonist)

A non-aromatizable, DHT-derived androgen receptor agonist originally developed by Syntex and approved for palliative treatment of advanced breast cancer in postmenopausal women, distinguished from other anabolic-androgenic steroids by its 2-alpha-methyl substitution conferring resistance to 3-alpha-hydroxysteroid dehydrogenase metabolism and a favorable anabolic-to-androgenic activity ratio.

Abstract

Masteron is the principal trade name for drostanolone propionate, the 17-beta-propionate ester of 2-alpha-methyl-5-alpha-dihydrotestosterone (2-alpha-methyl-DHT), a synthetic androstane steroid first described in 1959 and introduced to clinical medicine in 1961 following United States Food and Drug Administration approval for the palliative treatment of advanced, inoperable, androgen-responsive mammary carcinoma in postmenopausal women. The compound was developed by Syntex Corporation, licensed to Eli Lilly and Company, and marketed in the United States as Drolban and in European and other international markets as Masteril, Masteron, and Permastril. Drostanolone is a direct structural derivative of dihydrotestosterone (DHT) bearing a methyl group at the carbon-2 alpha position, a modification that confers two pharmacologically consequential properties: resistance to metabolic inactivation by 3-alpha-hydroxysteroid dehydrogenase (3-alpha-HSD) in skeletal muscle tissue, resulting in enhanced anabolic potency relative to the parent DHT molecule; and retention of the intrinsic non-aromatizability of the 5-alpha-reduced steroid nucleus, ensuring that the compound cannot be converted to estrogenic metabolites by the aromatase enzyme complex. As an androgen receptor (AR) agonist, drostanolone binds the AR with high affinity and initiates the canonical genomic androgen signaling cascade, including nuclear translocation, receptor dimerization, coactivator recruitment, and transcriptional activation of androgen-responsive genes governing protein synthesis, nitrogen retention, and musculoskeletal anabolism.

The clinical pharmacology of drostanolone propionate is defined by its intramuscular depot formulation. The propionate ester is hydrolyzed in vivo by tissue and plasma esterases to release the active drostanolone moiety, with an elimination half-life of approximately 2 to 3 days following intramuscular injection. The compound is not orally bioavailable owing to the absence of a 17-alpha-alkyl group; this same structural feature eliminates the hepatotoxicity risk associated with oral anabolic-androgenic steroids such as methyltestosterone and oxymetholone. Protein binding is high, predominantly to sex hormone-binding globulin (SHBG) and albumin. Metabolism proceeds through reduction and conjugation pathways; the principal urinary metabolites include 2-alpha-methyl-5-alpha-androstan-3-alpha-ol-17-one and its glucuronide and sulfate conjugates, which serve as the analytical targets for anti-doping detection.

The registered clinical indication was the palliation of advanced breast cancer in women who were more than one year but less than five years postmenopausal, with documented androgen-responsive or estrogen-receptor-positive disease that had progressed following initial endocrine therapies. Early clinical trials reported objective response rates of approximately 20 to 30 percent, including partial tumor regression and symptomatic palliation. The antitumor mechanism was attributed to competitive androgen receptor-mediated antagonism of estrogen-dependent tumor proliferation, with additional evidence suggesting inhibition of prolactin receptor expression and downregulation of estrogen receptor density in mammary tissue. The clinical application of drostanolone propionate and other androgenic agents in breast cancer was largely superseded in the 1970s and 1980s by the introduction of selective estrogen receptor modulators (tamoxifen) and subsequently by aromatase inhibitors (anastrozole, letrozole, exemestane), which offered comparable or superior efficacy with substantially reduced virilization burden. Drostanolone propionate is no longer marketed in any jurisdiction for the breast cancer indication.

The compound persists in contemporary relevance principally through its widespread non-medical use in performance and physique enhancement contexts, where it is valued for its non-aromatizable androgenic profile, its favorable anabolic-to-androgenic ratio, and its relatively mild side-effect burden compared to other injectable anabolic-androgenic steroids. Drostanolone is classified as a prohibited substance by the World Anti-Doping Agency (WADA) under the category of anabolic agents (S1) and is detectable in urine for up to 3 to 4 weeks following administration through gas chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry analysis of phase II metabolite conjugates. This monograph reviews the chemistry, synthesis, and stereochemistry of drostanolone propionate; the androgen receptor-mediated mechanism of action including antiestrogenic activity in mammary tissue; the pharmacokinetic profile of the propionate and enanthate ester formulations; the preclinical pharmacology; the clinical evidence base in breast cancer and related indications; sourcing and quality verification considerations; reconstitution and handling; stack interactions with other androgenic and ancillary compounds; adverse events and safety signals; and a comparative assessment of five alternative androgenic or antiestrogenic agents against drostanolone propionate on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1550Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
Livagen

Our opinion on this compoundSingle-lab provenance

43/100

Mechanistically rich Khavinson tetrapeptide hamstrung by absent independent replication

Livagen (KEDA: Lys-Glu-Asp-Ala) is one of the more mechanistically ambitious entries in the Khavinson bioregulator catalog, which is both the strongest thing you can say about it and the source of its fundamental problem. The peptide comes from the St. Petersburg Institute of Bioregulation and Gerontology, the same group that produced Epitalon, Vilon, Cortagen, and a dozen other short-peptide bioregulators. That pedigree means genuine scientific creativity and a consistent body of preclinical work from one source. It also means almost no independent replication, and in 2026 that matters a great deal.

The mechanism story is unusually rich for a four-amino-acid sequence. Three distinct claimed activities: first, induction of chromatin decondensation in aged lymphocytes and hepatocytes, with reactivation of ribosomal genes and euchromatic loci silenced during aging; second, potent inhibition of enkephalin-degrading serum peptidases at roughly 20 micromolar IC50, which the source literature claims exceeds reference inhibitors including puromycin, leupeptin, and D-phenylalanyl-alanyl-arginine-p-nitroanilide; and third, restoration of protein synthesis rhythms in senescent hepatocyte cultures at nanomolar concentrations. We think the enkephalinase inhibition angle is the most interesting of the three. Thats not a claim you typically see from this compound class, and if it survives outside the source lab, it opens real questions about opioid peptide half-life in aged tissue and how a simple tetrapeptide achieves that potency without direct opioid receptor interaction.

The problem is that qualifier: if it survives. The chromatin work closely mirrors the Epitalon telomere-activation narrative, which is plausible aging epigenetics but has spent decades stuck in the same institutional literature. The enkephalinase data is from in vitro serum work in one lab. Hepatoprotective preclinical evidence comes from rat models at the same address. The strongest independent-adjacent data is ex vivo human lymphocyte work showing chromatin changes, which is genuinely interesting but a considerable distance from a randomized trial. There are no registration-quality clinical studies on pure KEDA. The liver-targeting rationale leans on inference from the parent glandular preparation rather than direct pharmacokinetic data on the isolated tetrapeptide.

For a bench investigator, Livagen has real probe potential under specific conditions: hepatic aging biology, epigenetic reactivation in senescent cells, or opioid peptide degradation kinetics in aged tissue. The sequence is short, synthesis is clean, the mechanistic claims are falsifiable. Thats a legitimate pitch for someone building a research program around one of those questions who wants a low-MW epigenetic tool with a hepatic angle that isnt just another SAMe or silymarin analog.

Honestly though, the compound sits awkwardly between categories. Not a conventional hepatoprotectant, not a clean telomerase activator, not a GHRP analog. It would take a researcher willing to build from first principles rather than slot it into an established model. The score reflects what we think the evidence actually supports: a genuinely interesting hypothesis set from a source with a credibility problem it has not resolved.

Novelty

55

Mechanism promise

60

In-category differentiation

42

Evidence quality

22

Translational signal

20

Research bench value

48

Rationale Livagen’s three claimed mechanisms (chromatin decondensation, enkephalinase inhibition, hepatoprotection) are genuinely differentiated from sibling Khavinson peptides like Epitalon, and the enkephalinase IC50 claim exceeding reference inhibitors is a specific, falsifiable hypothesis worth attention; but essentially the entire evidence base traces to a single postal code in St. Petersburg, and without independent replication the multi-mechanism story cannot be weighted heavily.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic tetrapeptide bioregulator with hepatoprotective, epigenetic chromatin-remodeling, and enkephalinase-inhibitory activity

A Khavinson-class synthetic tetrapeptide (Lys-Glu-Asp-Ala) developed at the St. Petersburg Institute of Bioregulation and Gerontology as a liver-targeted bioregulator, distinguished by its capacity to induce chromatin decondensation in aged cells, inhibit enkephalin-degrading enzymes in human serum, and restore hepatocyte protein synthesis in senescent tissue.

Abstract

Livagen (Lys-Glu-Asp-Ala; single-letter code KEDA) is a synthetic tetrapeptide bioregulator developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology as a liver-targeted member of the broader Khavinson short-peptide bioregulator family. The compound is characterized by three principal pharmacological activities studied across cell culture, animal, and limited human research: (1) epigenetic chromatin remodeling through induction of deheterochromatinization of pericentromeric structural heterochromatin and facultative heterochromatin in lymphocytes and hepatocytes from aged organisms, with consequent reactivation of ribosomal genes and euchromatic loci silenced during aging; (2) potent inhibition of enkephalin-degrading serum peptidases (IC50 approximately 20 micromolar), exceeding the inhibitory potency of established peptidase inhibitors including puromycin, leupeptin, and D-phenylalanyl-alanyl-arginine-p-nitroanilide, without direct interaction with mu or delta opioid receptors; and (3) restoration of protein synthesis rhythms and metabolic function in hepatocyte cultures from aged rats to levels characteristic of young animals at nanomolar concentrations.

The chromatin-remodeling mechanism has been demonstrated in cultured lymphocytes from human subjects aged 75 to 88 years, in which Livagen induced activation of ribosomal genes, decondensation of pericentromeric heterochromatin of chromosomes 1, 9, and 16, and release of genes repressed through age-related condensation of euchromatic regions. This deheterochromatinization effect is shared with other Khavinson bioregulator peptides (Vilon, Epitalon, Cortagen) but appears tissue-preferential for hepatic and lymphoid lineages at the concentrations studied. Molecular modeling studies of the broader Khavinson peptide class suggest that short peptides interact with the nucleosome, histone proteins, and double-stranded DNA through steric and electrostatic complementarity, altering histone modification patterns and the accessibility of regulatory regions to transcription factors.

In experimental models of liver pathology (acute and chronic hepatitis, liver fibrosis), the KEDA tetrapeptide demonstrated hepatoprotective and immunoprotective effects including normalization of total bilirubin, cholesterol, alanine aminotransferase, and aspartate aminotransferase levels; stimulation of tissue repair; and decreased destructive dystrophic processes in liver stroma. The maximal hepatoprotective effect was observed in aged animals, consistent with the bioregulator hypothesis that these peptides primarily restore age-depleted signaling. In aged rat hepatocyte cultures, Livagen restored circahoralian rhythms of protein synthesis to patterns characteristic of young specimens at nanomolar concentrations. A separate line of investigation demonstrated that oral administration of Livagen for two weeks modulated digestive enzyme activity in rats in an age-dependent manner, reducing enzyme activity in young animals while increasing it in old animals toward levels observed in young controls.

The compound is resistant to hydrolysis by small intestinal peptidases and is not degraded to a measurable extent by the peptide hydrolases of the small intestine. Formal pharmacokinetic characterization meeting Western regulatory standards has not been published. The compound is not approved by any major Western regulatory authority (FDA, EMA) and is not registered on ClinicalTrials.gov. The primary research literature originates from Russian and Georgian institutions, and independent Western replication of key findings remains limited. This monograph reviews the chemistry, epigenetic pharmacology, hepatoprotective and digestive enzyme evidence, the limited pharmacokinetic record, sourcing and quality considerations, and a comparative assessment of five alternative hepatoprotective or epigenetic bioregulator compounds against Livagen on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1509Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
Alpha-Klotho

Our opinion on this compoundNovel frontier

78/100

The founding longevity-axis protein with paradigm-level multi-pathway mechanism and strong preclinical foundation

Look, alpha-Klotho is one of those proteins that makes serious longevity researchers stop and pay attention. When Kuro-o’s group published in 1997 that a single insertional mutation in mice produced a syndrome of premature aging — soft tissue calcification, arteriosclerosis, osteoporosis, emphysema, dramatically shortened lifespan — it wasnt just interesting. It was the first time a single gene loss had recapitulated aging this completely. And when overexpression of the same gene extended mouse lifespan by 20-30%, the field had its clearest argument yet that aging is regulated biology, not just entropy.

What we find genuinely compelling is the mechanism breadth. Most longevity targets hit one pathway. Klotho hits several simultaneously through distinct biochemical modes. As the obligate co-receptor for FGF23, it controls phosphate and vitamin D homeostasis at the kidney level. As a circulating endocrine factor, soluble klotho (sKL) inhibits insulin/IGF-1 signaling through a PI3K mechanism, Wnt signaling by sequestering Wnt ligands, TGF-beta signaling by direct receptor binding, and NF-kappaB driven inflammation. Four major aging-relevant pathways addressed by one shed ectodomain. The rubric we use lists klotho-axis modulators as a paradigm-shifting mechanism category, and its hard to argue with that placement when you map the biology.

The preclinical evidence base is solid and multi-lab: renoprotective effects replicated across CKD models, cardioprotective activity confirmed in heart failure models, and neuroprotection including Dubal group data showing that even a single copy of the KL-VS haplotype improves cognitive function in aging humans. That genetic finding, replicated in multiple independent cohorts, is one of the cleaner translational signals in longevity biology. Serum klotho declining with age and correlating inversely with cardiovascular and cognitive outcomes has been confirmed in large epidemiological datasets including NHANES-derived analyses and the Osteoporotic Fractures in Men cohort.

Honestly, the weakest part of the story is the interventional gap. No completed phase 2 or 3 trials exist for exogenous klotho administration. Recombinant alpha-klotho is a large, difficult-to-produce protein with real pharmacokinetic challenges around half-life and delivery. Several gene therapy vectors and small molecule klotho inducers are in early development, but we’re still waiting on the first clean interventional proof-of-concept in humans. That gap is real, and it’s what holds the evidence and translational scores to the 55-60 range despite the quality of the observational data.

For bench researchers, this remains one of the more important tools in the longevity space. The kl/kl mouse is a foundational aging model. Recombinant sKL has genuine utility as a signaling probe for FGF23 biology, Wnt modulation studies, and multi-pathway aging mechanism work. The KL-VS haplotype is a validated genetic handle for human cognitive aging studies. We think the 78 overall reflects exactly where klotho sits right now: mechanistically elite, evidentially developing, and genuinely among the most interesting targets the field has produced in the last three decades.

Novelty

85

Mechanism promise

90

In-category differentiation

87

Evidence quality

55

Translational signal

60

Research bench value

83

Rationale Alpha-klotho scores high on novelty and mechanism because it defines an entirely new aging-suppression axis with multi-pathway pleiotropic activity the spec explicitly names as paradigm-shifting; evidence and translational scores are constrained by the absence of completed interventional clinical trials, but replicated genetic epidemiology provides a real human signal.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Type I transmembrane protein and circulating endocrine factor of the glycosyl hydrolase family 1 superfamily with obligate FGF23 co-receptor and pleiotropic anti-aging functions

A kidney-derived transmembrane glycoprotein and its shed soluble ectodomain, identified through insertional mutagenesis in 1997 as a suppressor of aging phenotypes in mice, functioning both as an obligate co-receptor for fibroblast growth factor 23 in mineral metabolism and as a circulating endocrine factor that inhibits insulin/IGF-1, Wnt, TGF-beta, and NF-kappaB signaling pathways with demonstrated neuroprotective, cardioprotective, and renoprotective activity in preclinical models.

Abstract

Alpha-Klotho (alpha-KL) is a 130 kDa type I single-pass transmembrane protein encoded by the KL gene on human chromosome 13q13.1, first identified in 1997 by Kuro-o et al. through characterization of an insertional mutation in mice that produced a syndrome of accelerated aging encompassing soft tissue calcification, arteriosclerosis, skin atrophy, osteoporosis, emphysema, gonadal dysplasia, and dramatically shortened lifespan [1]. The protein comprises a short intracellular domain, a single transmembrane helix, and a large extracellular region containing two tandem glycosyl hydrolase family 1 (GH1) domains, designated KL1 and KL2, which share sequence homology with family 1 beta-glucosidases but lack catalytic activity against conventional substrates due to substitutions in the active-site residues. The extracellular domain undergoes proteolytic shedding by ADAM10, ADAM17, and BACE1, generating a soluble ectodomain (sKL) comprising KL1 and KL2 that circulates as an endocrine factor detectable in plasma, cerebrospinal fluid, and urine. A shorter secreted isoform containing only KL1 is produced by alternative mRNA splicing.

In its membrane-bound form, alpha-Klotho functions as an obligate co-receptor for fibroblast growth factor 23 (FGF23), forming a ternary complex with FGF receptor 1c (FGFR1c) that is essential for phosphaturic signaling in the renal proximal tubule and for suppression of 1,25-dihydroxyvitamin D3 (calcitriol) synthesis. The crystal structure of the alpha-Klotho/FGFR1c/FGF23 ternary complex, resolved by Chen et al. (2018) at 3.0 angstrom resolution, demonstrated that the KL2 domain of alpha-Klotho cradles FGF23 with a receptor-binding arm extending from the KL1-KL2 interdomain cleft, creating a composite binding surface for FGF23 engagement [2]. Loss of this co-receptor function produces the hyperphosphatemia, hypervitaminosis D, and ectopic calcification that characterize the kl/kl mouse phenotype and that are recapitulated in FGF23 knockout mice.

Independent of the FGF23 co-receptor function, soluble alpha-Klotho acts as a circulating endocrine factor with pleiotropic anti-aging activity. Characterized signaling activities include inhibition of the insulin/insulin-like growth factor 1 (IGF-1) pathway through suppression of receptor autophosphorylation; suppression of Wnt/beta-catenin signaling through direct binding to Wnt ligands; inhibition of transforming growth factor beta (TGF-beta) type II receptor signaling and downstream Smad phosphorylation; suppression of NF-kappaB-driven inflammatory transcription; and regulation of ion channel and transporter activity in the renal tubule, including TRPV5, TRPV6, ROMK1, and the Na+/K+-ATPase [3, 4, 5]. These FGF23-independent activities are the molecular basis for the broader anti-aging, neuroprotective, cardioprotective, and anti-fibrotic effects observed in gain-of-function and supplementation studies.

Circulating soluble alpha-Klotho levels decline with age in humans, beginning approximately in the fourth decade of life, and are markedly reduced in chronic kidney disease, where loss of renal alpha-Klotho expression precedes and contributes to the mineral and bone disorder, cardiovascular calcification, and accelerated aging phenotype of uremia [6]. Epidemiological studies have identified inverse associations between circulating soluble alpha-Klotho concentrations and all-cause mortality, cardiovascular events, and cognitive decline in community-dwelling older adults [7]. The KL-VS haplotype (defined by the F352V and C370S variants, rs9536314 and rs9527025) has been associated in some cohorts with altered klotho secretion, cortical brain volume, and cognitive resilience in aging, though replication across large cohorts remains inconsistent [8, 9].

Preclinical studies have demonstrated that recombinant alpha-Klotho protein administration, adeno-associated virus-mediated KL gene transfer, and transgenic KL overexpression produce renoprotection in ischemia-reperfusion injury and unilateral ureteral obstruction models; cardioprotection with attenuation of left ventricular hypertrophy and fibrosis; suppression of vascular calcification; and cognitive enhancement in aged, young, and alpha-synuclein transgenic mice through NMDA receptor-dependent glutamatergic mechanisms [10, 11, 12, 13]. A 2023 study in aged nonhuman primates demonstrated that a single subcutaneous injection of a klotho protein fragment enhanced spatial and working memory, representing the first primate cognitive enhancement data for the compound [14].

As of 2026, alpha-Klotho is in early clinical development. Klothea Bio launched a Phase 1b randomized, double-blind, placebo-controlled trial of AKL003, an alpha-Klotho mRNA therapeutic administered intravenously, in healthy adult volunteers in February 2026. Klotho Neurosciences is advancing KLTO-202, a KL gene therapy, toward first-in-human studies for amyotrophic lateral sclerosis. No alpha-Klotho protein or gene therapy product has received regulatory approval in any jurisdiction. Recombinant human alpha-Klotho protein is available from multiple research suppliers (R&D Systems, Abcam, Sino Biological, Thermo Fisher) for in vitro and preclinical applications. This monograph reviews the molecular identification, structural biology, receptor pharmacology, preclinical pharmacology across organ systems, the emerging clinical evidence base, sourcing and handling considerations, stack interactions, safety signal, and a comparative assessment of five anti-aging intervention candidates against alpha-Klotho on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1512Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
Aminotadalafil

Our opinion on this compoundLow merit

14/100

Forensic adulterant reference with no independent research program or novel mechanism

Look, aminotadalafil exists in the biomedical literature for one reason: someone found it in a supplement that was supposed to be herbal, and analytical labs needed a reference standard to confirm the hit. Thats not a research program. That’s a forensic problem, and treating it as the former because the latter requires it is a mistake worth naming explicitly.

The structural story is as simple as it gets. Swap the N-methyl on tadalafil’s piperazinedione ring for a primary amine and you have aminotadalafil. One functional group change. The beta-carboline scaffold is intact, PDE5 active-site recognition is preserved, and cross-reactivity with anti-tadalafil polyclonal antibodies runs above 100 percent. So yes, it almost certainly inhibits PDE5. We already knew that from the class. There is no new mechanism here, no dual-target angle, no allosteric surprise waiting to be characterized. PDE5 inhibition is about as mature a mechanism as phosphodiesterase biology gets: sildenafil, tadalafil, vardenafil, and avanafil have been in clinical use for decades, the crystal structures are solved, selectivity profiles are mapped across the PDE superfamily, and the downstream cGMP-nitric oxide pathway is textbook. Aminotadalafil contributes nothing to that picture.

What makes this compound genuinely uninteresting as a research candidate is the evidence situation. There is no formal pharmacokinetic characterization. No rodent toxicology package. No human pharmacology trial of any kind. The closest thing to translational data is an adverse event corpus drawn from people who consumed adulterated supplements without knowing it, which isnt a controlled exposure arm by any stretch. You cant extract clean pharmacology from that. The differentiation case is equally grim: if you need a PDE5 inhibitor for bench work, tadalafil is commercially available, comes with established handling protocols, and carries decades of selectivity data. Aminotadalafil is, by every research metric, inferior to its own parent. Strictly so.

We think the only legitimate use case here is as a certified reference material for regulatory or analytical chemistry labs running supplement screening panels. That work matters, it’s genuinely important for consumer safety, but it isnt what a research compound library is built to support. The library is for compounds that give investigators new angles on a biological question. Aminotadalafil doesn’t do that. It’s a known adulterant, a forensic footnote, and a reminder that the supplement industry operates a shadow pharmacopoeia with no clinical trial infrastructure behind it. A bench scientist looking for a PDE5 probe should reach for tadalafil without hesitation. A lab building a supplement adulterant detection panel should source aminotadalafil as a reference standard. Those are different jobs, and this compound belongs only in the second.

Novelty

18

Mechanism promise

15

In-category differentiation

8

Evidence quality

12

Translational signal

10

Research bench value

22

Rationale Aminotadalafil appears in the literature almost exclusively as a dietary supplement adulterant flagged by regulatory enforcement labs; PDE5 inhibition is a fully saturated mechanism with multiple approved parent compounds, and the complete absence of formal pharmacology data leaves this analog with near-zero bench value except as an analytical reference standard for detection assays.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Synthetic phosphodiesterase type 5 (PDE5) inhibitor analog; tadalafil N-methyl-to-amino substituted derivative

A synthetic structural analog of tadalafil in which the piperazinedione N-methyl group is replaced by a primary amine, yielding an unapproved phosphodiesterase type 5 inhibitor principally encountered as an undeclared adulterant in dietary supplements marketed for erectile dysfunction.

Abstract

Aminotadalafil, formally (6R,12aR)-2-amino-6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydropyrazino[1′,2′:1,6]pyrido[3,4-b]indole-1,4-dione (CAS 385769-84-6), is a synthetic structural analog of tadalafil, the selective cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) inhibitor marketed as Cialis for the treatment of erectile dysfunction, pulmonary arterial hypertension, and benign prostatic hyperplasia. The single structural modification that distinguishes aminotadalafil from the parent drug is the replacement of the N-methyl substituent on the 2-position of the piperazinedione (diketopiperazine) ring with a primary amino group (NH2), a change that alters hydrogen-bonding capacity, basicity, and physicochemical properties while preserving the core beta-carboline-fused diketopiperazine scaffold responsible for PDE5 active-site recognition. Aminotadalafil retains inhibitory activity at PDE5 and exhibits greater than 100 percent cross-reactivity with anti-tadalafil polyclonal antibodies, confirming close structural and immunochemical homology with the parent compound [1]. The compound has not undergone formal preclinical toxicology, human pharmacokinetic characterization, or clinical efficacy evaluation in any regulatory jurisdiction, and it is not approved for human use by any national medicines authority. Its principal significance in the biomedical literature arises from its repeated identification as an undeclared adulterant in dietary supplements, herbal products, and electronic cigarette liquids marketed for sexual enhancement, where it poses uncharacterized risks to consumers who are unaware of its presence and who may be concurrently taking nitrate-containing medications or other agents that interact with the cGMP-nitric oxide signaling pathway [2, 3, 4, 5].

The analytical chemistry literature on aminotadalafil is substantial. The compound has been identified and structurally characterized by proton and carbon-13 nuclear magnetic resonance spectroscopy, electrospray ionization mass spectrometry, Fourier transform infrared spectroscopy, and ultraviolet spectrophotometry in dietary supplement matrices across multiple continents, including reports from Latin America, Asia, Europe, and North America [2, 6, 7]. Validated high-performance liquid chromatography with diode array detection (HPLC-DAD) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods permit simultaneous identification and quantification of aminotadalafil alongside other PDE5 inhibitor analogs (hydroxythiohomosildenafil, thiosildenafil, dimethylsildenafil, thiodimethylsildenafil) in complex supplement matrices [3, 8]. A dimeric interaction product of aminotadalafil has also been isolated from adulterated health food products, suggesting that the compound undergoes degradation or condensation reactions under storage conditions encountered in supplement manufacture [9].

The pharmacological characterization of aminotadalafil is limited. No peer-reviewed study has reported a direct IC50 determination for aminotadalafil against recombinant human PDE5, and no selectivity panel across the eleven mammalian phosphodiesterase families has been published. The compound’s activity is inferred from its structural homology to tadalafil (IC50 approximately 1.8 to 5.0 nanomolar against PDE5) and from the immunochemical cross-reactivity data. Structure-activity relationship studies of the broader tadalafil analog series indicate that modifications at the 2-position of the diketopiperazine ring modulate PDE5 affinity, and that the (6R,12aR) stereochemistry derived from L-tryptophan is essential for potent inhibition [10, 11]. Aminotadalafil preserves this stereochemistry. No human pharmacokinetic, dose-response, or safety data exist; toxicological risk assessment must therefore rely on extrapolation from tadalafil and on the general pharmacology of the PDE5 inhibitor class. This monograph reviews the chemistry, structural pharmacology, inferred pharmacokinetics, regulatory history, detection methodology, sourcing considerations, and comparative assessment of aminotadalafil against five alternative PDE5 inhibitor analogs encountered in the adulterated supplement landscape.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1543Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026
Emodin

Our opinion on this compoundEstablished workhorse

32/100

Active preclinical subject with multi-target MoA, but clinical translation is nearly absent and safety baggage is real

Look, emodin has been kicking around in pharmacology longer than most investigators have been alive. The anthraquinone backbone was first isolated from Himalayan rhubarb in the 19th century, and Rheum palmatum preparations have two millennia of traditional use behind them. Thats not novelty; thats a compound that modern pharmacology keeps reexamining hoping to find something it missed. Sometimes that pays off. Here, the verdict is mixed.

The mechanism story is legitimately interesting on paper. Emodin isn’t a single-target molecule: it inhibits NF-kB transcriptional activity, activates AMPK, suppresses the PI3K/Akt/mTOR axis, directly inhibits casein kinase II and p56lck, and modulates STAT3 and HIF-1alpha. That composite profile spans anti-inflammatory, antitumor, antifibrotic, antiviral, and metabolic territories. We’d be more impressed if this breadth translated into selectivity for any one research program, but it doesn’t. When a compound hits NF-kB, AMPK, mTOR, and multiple kinases simultaneously, you’re not running clean experiments. The promiscuity that makes the pharmacology look rich is exactly what makes emodin a poor probe.

The preclinical literature is genuinely multi-lab and spans a wide range of models: hepatocellular carcinoma, pancreatic cancer, colitis, NAFLD, renal fibrosis, and viral targets including SARS-CoV-2 protease inhibition. There’s no shortage of data. What there is a shortage of is any clean, well-designed human trial on emodin itself. The clinical section of this monograph covers traditional herbal formulations and diacerein, a pro-drug of the structurally related rhein, which actually achieved regulatory approval for osteoarthritis in some jurisdictions. Emodin specifically has not cleared that bar, and the barriers are not trivial: dose-dependent hepatotoxicity, nephrotoxicity at higher exposures, genotoxicity signals in multiple assays, and reproductive toxicity findings that complicate any serious IND-level conversation. Bioavailability is also a chronic problem, with extensive first-pass metabolism and poor systemic exposure from oral dosing.

What we think emodin is useful for: anthraquinone class characterization, comparative structure-activity work within the Polygonaceae-derived compound space, and as a reference compound in NF-kB or CKII inhibition assays where its activity is well-documented enough to serve as a positive control. What it isn’t useful for: anchoring a serious translational research program. The literature is wide and shallow, the safety profile limits what you can do with it in vivo, and any effect you observe is mechanistically ambiguous by design.

Honestly, if your program is metabolic or oncologic, you have better-characterized tools. If you’re specifically studying anthraquinone pharmacology or TCM-adjacent natural product chemistry, emodin is the reference compound by volume of literature. That’s a real but narrow role, and the score reflects it.

Novelty

22

Mechanism promise

50

In-category differentiation

32

Evidence quality

33

Translational signal

18

Research bench value

40

Rationale Emodin is a decades-old natural product with genuine mechanistic breadth (NF-kB, AMPK, CKII, PI3K/Akt/mTOR) and a large multi-lab preclinical footprint, but the clinical evidence base for isolated emodin is essentially nil, the translational arrow is weak due to hepatotoxicity and genotoxicity signals, and the compound is too promiscuous to serve as a clean probe. Scores land it in the lower established-mature band with no applicable hard cap.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Natural anthraquinone derivative with multi-target anti-inflammatory, antitumor, and metabolic regulatory activity

A 1,3,8-trihydroxy-6-methylanthraquinone isolated from Rheum palmatum and related Polygonaceae species, characterized by pleiotropic pharmacology spanning NF-kappaB inhibition, AMPK activation, kinase modulation, and broad-spectrum antimicrobial activity, with longstanding traditional use and emerging preclinical validation across oncology, metabolic disease, and inflammatory indications.

Abstract

Emodin (1,3,8-trihydroxy-6-methylanthraquinone; CAS 518-82-1) is a naturally occurring anthraquinone derivative present in the roots and rhizomes of multiple medicinal plant species, most notably Rheum palmatum L. (Chinese rhubarb), Polygonum cuspidatum (Japanese knotweed), Polygonum multiflorum (He Shou Wu), Cassia obtusifolia, and Aloe vera. The compound has been a constituent of traditional Chinese medicine preparations for over two millennia, with rhubarb first recorded in the Shen Nong Ben Cao Jing, the earliest systematic pharmacopoeia of traditional Chinese medicine. Modern pharmacological investigation has revealed emodin to be a pleiotropic bioactive molecule operating through multiple convergent signaling pathways, including inhibition of nuclear factor kappa B (NF-kappaB) transcriptional activity, activation of AMP-activated protein kinase (AMPK), suppression of the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) axis, modulation of peroxisome proliferator-activated receptor gamma (PPARgamma), and direct inhibition of casein kinase II (CKII) and the protein tyrosine kinase p56lck. These molecular activities produce a composite pharmacological profile encompassing anti-inflammatory, antitumor, antiviral, antibacterial, antifibrotic, hepatoprotective (at low doses), antidiabetic, and immunomodulatory effects demonstrated across extensive in vitro and in vivo preclinical models.

The antitumor activity of emodin has been characterized in cell culture and rodent xenograft models against pancreatic, hepatocellular, breast, lung, colorectal, and prostate carcinomas, with mechanisms including induction of caspase-dependent apoptosis, cell cycle arrest at the G2/M checkpoint, suppression of matrix metalloproteinase-mediated invasion, inhibition of angiogenesis through vascular endothelial growth factor downregulation, and reversal of gemcitabine resistance through IKKbeta/NF-kappaB pathway suppression. The anti-inflammatory profile operates primarily through suppression of NF-kappaB-driven proinflammatory cytokine release (tumor necrosis factor alpha, interleukin-1 beta, interleukin-6) and through NLRP3 inflammasome inhibition. Antiviral activity has been demonstrated against more than ten viral species in vitro and in vivo, including herpes simplex virus types 1 and 2, influenza A virus, coxsackievirus B3, hepatitis B virus, and SARS-CoV. Antibacterial activity is notable against Gram-positive organisms, with minimum inhibitory concentrations against Staphylococcus aureus and Mycobacterium tuberculosis in the low-micromolar range.

The principal pharmacokinetic limitation of emodin is extremely poor oral bioavailability, approximately 3 percent in rodent models, attributable to rapid and extensive phase II glucuronidation by UDP-glucuronosyltransferases (UGT1A1, UGT1A9, UGT2B7) in both intestinal epithelium and hepatocytes, with additional contributions from CYP1A2 and CYP2E1 oxidative metabolism. Approximately 56 percent of an oral dose is unabsorbed and excreted in feces as parent compound. This pharmacokinetic barrier has substantially limited clinical translation despite extensive preclinical efficacy data. Strategies to overcome poor bioavailability include co-administration with the glucuronidation inhibitor piperine (which produces a 221 percent increase in area under the curve in rodent models), nanoparticle encapsulation, liposomal formulation, polymeric lipid hybrid nanoparticles, and solid lipid nanoparticle delivery systems.

Toxicological evaluation has identified dose-dependent hepatotoxicity, nephrotoxicity, and reproductive toxicity at sustained high doses. Hepatotoxicity is mediated in part through inhibition of hepatocyte nuclear factor 4 alpha expression and consequent downregulation of UGT2B7, creating a paradoxical positive feedback loop in which high-dose emodin impairs its own principal detoxification pathway. Nephrotoxicity occurs through induction of apoptosis in proximal tubular epithelial cells via PPARgamma-related mitochondrial pathways. Reproductive toxicity includes disruption of testicular gene expression and inhibition of human sperm calcium signaling and tyrosine phosphorylation in vitro. The compound is not approved as a pharmaceutical agent by any major regulatory authority. It is classified as a dietary supplement ingredient and research compound. This monograph reviews the chemistry, natural sourcing, and structural characterization of emodin; the multi-pathway molecular pharmacology; the comprehensive pharmacokinetic record including glucuronidation-dominated metabolism; the preclinical evidence base across oncology, inflammatory, metabolic, infectious disease, and fibrotic indications; the limited clinical evidence; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; the adverse-event and toxicity profile; and a structured comparative assessment of five anthraquinone derivatives (chrysophanol, rhein, aloe-emodin, diacerein, physcion) against emodin on five competency standards.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-1540Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 15, 2026

←Previous Page

1 … 12 13 14 15 16 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.